Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populations

Cell Cycle

Volumn 11, Issue 2, 2012, Pages 310-321

  Schnerch, Dominik ^a   Follo, Marie ^a   Krohs, Julika ^a   Felthaus, Julia ^a   Engelhardt, Monika ^a   Wäsch, Ralph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anaphase promoting complex; Cyclin B; Genomic stability; Mitotic exit; Spindle assembly checkpoint

Indexed keywords

ANAPHASE PROMOTING COMPLEX; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COMPLEMENTARY DNA; CYCLIN B; CYCLOHEXIMIDE; NOCODAZOLE; RNA; SECURIN;

ARTICLE; CELL CYCLE; CHROMOSOME SEGREGATION; ENZYME INACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MITOSIS; MITOSIS SPINDLE; PROTEIN DEGRADATION;

EID: 84856120839     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.11.2.18737     Document Type: Article

References (24)

1. Wäsch R, Cross FR. APC-dependent proteolysis of the mitotic cyclin Clb2 is essential for mitotic exit. Nature 2002; 418:556-62; PMID:12152084; http://dx.doi.org/10.1038/nature00856.
2. Wolf F, Wandke C, Isenberg N, Geley S. Dose-dependent effects of stable cyclin B1 on progression through mitosis in human cells. EMBO J 2006; 25:2802-13; PMID:16724106; http://dx.doi.org/10.1038/sj.emboj.7601163.
3. Visintin R, Craig K, Hwang ES, Prinz S, Tyers M, Amon A. The phosphatase Cdc14 triggers mitotic exit by reversal of Cdk-dependent phosphorylation. Mol Cell 1998; 2:709-18; PMID:9885559; http://dx.doi.org/10.1016/S1097-2765(00) 80286-5.
4. Schmitz MH, Held M, Janssens V, Hutchins JR, Hudecz O, Ivanova E, et al. Live-cell imaging RNAi screen identifies PP2A-B55alpha and importin-beta1 as key mitotic exit regulators in human cells. Nat Cell Biol 2010; 12:886-93; PMID:20711181; http://dx.doi.org/10.1038/ncb2092.
5. Pines J. Cubism and the cell cycle: the many faces of the APC/C. Nat Rev Mol Cell Biol 2011; 12:427-38; PMID:21633387; http://dx.doi.org/10.1038/nrm3132.
6. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8:379-93; PMID:17426725; http://dx.doi.org/10. 1038/nrm2163.
7. Visconti R, Palazzo L, Grieco D. Requirement for proteolysis in spindle assembly checkpoint silencing. Cell Cycle 2010; 9:564-9; PMID:20081372; http://dx.doi.org/10.4161/cc.9.3.10581.
8. Brito DA, Rieder CL. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 2006; 16:1194-200; PMID:16782009; http://dx.doi.org/10.1016/j.cub.2006.04.043.
9. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14:111-22; PMID:18656424; http://dx.doi.org/10.1016/j.ccr.2008.07. 002.
10. Huang HC, Shi J, Orth JD, Mitchison TJ. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009; 16:347-58; PMID:19800579; http://dx.doi.org/10.1016/j.ccr.2009.08.020.
11. Lee J, Kim JA, Margolis RL, Fotedar R. Substrate degradation by the anaphase promoting complex occurs during mitotic slippage. Cell Cycle 2010; 9:1792-801; PMID:20436289; http://dx.doi.org/10.4161/cc.9.9.11519.
12. Riffell JL, Zimmerman C, Khong A, McHardy LM, Roberge M. Effects of chemical manipulation of mitotic arrest and slippage on cancer cell survival and proliferation. Cell Cycle 2009; 8:3025-38; PMID:19713760; http://dx.doi.org/10. 4161/cc.8.18.9623.
13. Manchado E, Guillamot M, de Carcer G, Eguren M, Trickey M, Garcia-Higuera I, et al. Targeting mitotic exit leads to tumor regression in vivo: Modulation by Cdk1, Mastl and the PP2A/B55alpha,delta phosphatase. Cancer Cell 2010; 18:641-54; PMID:21156286; http://dx.doi.org/10.1016/j.ccr.2010.10.028.
14. Clute P, Pines J. Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1999; 1:82-7; PMID:10559878; http://dx.doi.org/10. 1038/10049.
15. Keppler A, Gendreizig S, Gronemeyer T, Pick H, Vogel H, Johnsson K. A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat Biotechnol 2003; 21:86-9; PMID:12469133; http://dx.doi.org/10. 1038/nbt765.
16. Jansen LE, Black BE, Foltz DR, Cleveland DW. Propagation of centromeric chromatin requires exit from mitosis. J Cell Biol 2007; 176:795-805; PMID:17339380; http://dx.doi.org/10.1083/jcb.200701066.
17. Mena AL, Lam EW, Chatterjee S. Sustained spindle-assembly checkpoint response requires de novo transcription and translation of cyclin B1. PLoS ONE 2010; 5:13037; PMID:20927403; http://dx.doi.org/10.1371/journal.pone.0013037.
18. Malureanu L, Jeganathan KB, Jin F, Baker DJ, van Ree JH, Gullon O, et al. Cdc20 hypomorphic mice fail to counteract de novo synthesis of cyclin B1 in mitosis. J Cell Biol 2010; 191:313-29; PMID:20956380; http://dx.doi.org/10.1083/ jcb.201003090.
19. Musacchio A. Cell cycle: deconstructing tension. Curr Biol 2010; 20:634-7; PMID:20692610; http://dx.doi.org/10.1016/j.cub.2010.06.014.
20. Groisman I, Jung MY, Sarkissian M, Cao Q, Richter JD. Translational control of the embryonic cell cycle. Cell 2002; 109:473-83; PMID:12086604; http://dx.doi.org/10.1016/S0092-8674(02)00733-X.
21. Winston NJ. Stability of cyclin B protein during meiotic maturation and the first mitotic cell division in mouse oocytes. Biol Cell 1997; 89:211-9; PMID:9429304; http://dx.doi.org/10.1016/S0248-4900(97)80037-8.
22. Ledan E, Polanski Z, Terret ME, Maro B. Meiotic maturation of the mouse oocyte requires an equilibrium between cyclin B synthesis and degradation. Dev Biol 2001; 232:400-13; PMID:11401401; http://dx.doi.org/10.1006/dbio.2001.0188.
23. Zeng X, Sigoillot F, Gaur S, Choi S, Pfaff KL, Oh DC, et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpointdependent mitotic arrest in the absence of spindle damage. Cancer Cell 2010; 18:382-95; PMID:20951947; http://dx.doi.org/10.1016/j.ccr.2010.08.010.
24. Engelbert D, Schnerch D, Baumgarten A, Wäsch R. The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells. Oncogene 2008; 27:907-17; PMID:17700535; http://dx.doi.org/10.1038/sj.onc. 1210703.